Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
